title: Controlled studies of Daflon 500 mg in chronic venous insufficiency.
abstract: Although great advances have been made in the operative treatment of vascular disorders, the management of most venous problems is still nonsurgical. Daflon 500 mg* is a micronized flavonoid mixture of 90% diosmin and 10% hesperidin that has phlebotonic properties. The efficacy of Daflon 500 mg has been investigated in three double-blind, randomized trials using strain gauge plethysmography to provide quantitative information on venous hemodynamics in patients with chronic venous insufficiency. In total, 183 patients were treated with Daflon 500 mg versus a control group of equal number of patients. Daflon 500 mg produced a significant decrease in venous capacitance, venous distensibility, and venous emptying time (P < 0.001). In addition, these changes were accompanied by improvement in clinical symptoms and a decrease in the supramalleolar circumference. Clinical side effects were rare and led to treatment withdrawal in only 3 patients. It is concluded that Daflon 500 mg is of benefit to patients with chronic venous insufficiency.
authors.affiliation: Academic Surgical Unit, St. Mary's Hospital Medical School, Imperial College of Science Technology and Medicine, London, England.
authors.forename: G
authors.initials: G
authors.lastname: Geroulakos
authors.forename: A N
authors.initials: AN
authors.lastname: Nicolaides
mesh_terms: D004145:Diosmin / Q000627:therapeutic use*; D004338:Drug Combinations; D005419:Flavonoids / Q000627:therapeutic use; D006569:Hesperidin / Q000627:therapeutic use*; D006801:Humans; D010991:Plethysmography; D016032:Randomized Controlled Trials as Topic; D014689:Venous Insufficiency / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D004338:Drug Combinations; D005419:Flavonoids; C080675:S 5682; D004145:Diosmin; D006569:Hesperidin